MotherToBaby

Medications and More during pregnancy and breastfeeding

Search

866.626.6847

Famotidine

Selected References:

  • Courtney TP, et al. 1988. Excretion of famotidine in breast milk. Br J Clin Pharmacol 26:639P.
  • Garbis H, et al. 2005. Pregnancy outcome after exposure to ranitidine and other H2-blockers. A collaborative study of the European Network of Teratology Information Services. Reprod Toxicol 19:453-8.
  • Hagemann, T. M. 1998. Gastrointestinal Medications and Breastfeeding. Journal of Human Lactation, 14(3), 259–262.
  • Kallen B. 1998. Delivery outcome after the use of acid-suppressing drugs in early pregnancy with special reference to omeprazole. Journal of Obstetrics and Gynecology 105:877-881.
  • Magee LA, et al.1996. Safety of first trimester exposure to histamine H2 blockers. A prospective cohort study. Dig Dis Sci 41(6):1145-1149.
  • Matok I, et al. 2010. The safety of H(2)-blockers use during pregnancy. J Clin Pharmacol 50(1):81-87.
  • Orenstein SR, Shalaby TM, Devandry SN et al. 2003. Famotidine for infant gastro-oesophageal reflux: A multi-centre, randomized, placebo-controlled, withdrawal trial. Aliment Pharmacol Ther. 7(9):1097-107.
  • Savarino V, et al. 1988. Famotidine has no significant effect on gonadal function in man. Gastroenterol Clin Biol 12:19-22.
  • Wang X, et al. 2011. Pharmacokinetics of famotidine in pregnant women. Am J Obstet Gynecol.; 204:S72-3.
  • Yitshak-Sade M, et al. 2016. Prenatal exposure to H2 blockers and to proton pump inhibitors and asthma development in offspring. J Clin Pharmacol.56(1):116-23.

This website is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling $6,000,000 with zero percentage financed with non-governmental sources. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, HRSA, HHS, or the U.S. Government.